Merck 1Q Revenues: $10.8 billion (+ 8%) 1Q Earnings: $2.9 billion (earnings were $736 million 1Q18) Comments: Keytruda sales were $2.3 billion in the quarter, up 55%. JANUVIA sales were down 5% to $1.4 billion due to continuing pricing pressure in the U.S. Growth in the quarter was partially offset by the ongoing impacts from the loss of market exclusivity for ZETIA and VYTORIN with sales down 50% to $238 million. Growth in vaccines was driven largely by GARDASIL, with sales of $838 million, ...